A Phase I Study of an Intravesically Administered Immunotoxin Targeting EpCAM for the Treatment of Nonmuscle-Invasive Bladder Cancer in BCG-refractory and BCG-intolerant Patients
Drug Design, Development and Therapy - New Zealand
doi 10.2147/dddt.s14071
Full Text
Open PDFAbstract
Available in full text
Date
November 1, 2010
Authors
Unknown
Publisher
Informa UK Limited
